Astellas and Adaptimmune Signs Co-Exclusive Agreement for Universal Donor Cell Platform and Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies

 Astellas and Adaptimmune Signs Co-Exclusive Agreement for Universal Donor Cell Platform and Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies

Astellas and Adaptimmune Signs Co-Exclusive Agreement for Universal Donor Cell Platform and Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies

Shots:

  • Adaptimmune to receive $50M up front, ~73.75M development milestones/ target (if product co-developed & co-commercialized by both companies) and $147.5M as milestones/product & $110M as commercial milestone if products developed by Astellas. Additionally, Adaptimmune to receive up to $7.5M/ yr. as research funding and royalties on net sales of the products
  • Astellas to receive and $147.5M as milestones/product & $110M as commercial milestone if products developed by Adaptimmune and royalties on net sales of the therapies. The companies will equally share the cost & profit of therapies co-develop & co-commercialize by the companies
  • The collaboration leverages Adaptimmune’s target identification and validation capabilities and Astellas’ universal donor cell and gene-editing platform. The agreement covers up to three T-cell therapies, following the completion of P-I study of each candidate, the companies will elect whether to co-develop & co-commercialize the candidate or allow the other company to develop in exchange of milestones & royalties

Click here ­to­ read full press release/ article | Ref: Adaptimmune | Image:  Adaptimmune

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post